Continuous glucose monitoring (CGM) is a tool, not a reward: Unjustified insurance coverage criteria limit access to CGM
Recent studies have demonstrated the clinical utility of continuous glucose monitoring (CGM) use in type 2 diabetes (T2D) patients who are treated with intensive insulin management. Large retrospective database analyses of T2D patients treated with less-intensive therapies have also shown that CGM u...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mary Ann Liebert Inc.
2021
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |